Archive · 2 Aug 2025
India Nears Completion of Phase III Dengue Vaccine Trials
India is testing a new vaccine called DengiAll to protect against dengue fever.
Researchers are conducting a large study with over 10,000 people in India to see how well the vaccine works.
The goal is to protect against all four types of the dengue virus.
The government is working hard to fight dengue with this trial, because dengue cases are high.
It is being tested at many hospitals in different areas of India, and it is hoped that this study will give a way to stop the virus.
Phase III trial for India's first dengue vaccine, DengiAll, is underway.
The ICMR is conducting the clinical study to evaluate the vaccine's efficacy.
Over 70% of the participants, exceeding 10,000, have been enrolled.
The trial is taking place at 20 research centers across India.
The study aims to test the vaccine's efficacy against all four dengue virus serotypes.
- Who
- The Indian Council of Medical Research (ICMR) and the Ministry of Health and Family Welfare.
- What
- Phase III trial of the DengiAll dengue vaccine is progressing with over 70% enrollment.
- When
- Ongoing trial
- Where
- 20 research centers across India.
- Why
- To evaluate the efficacy of the DengiAll vaccine against all four known serotypes of the dengue virus.
- Vaccine Name
- DengiAll
- Trial Phase
- Phase III
- Participants Enrolled
- Over 70%
- Number of Participants
- Over 10,000
- Trial Sites
- 20 across India
- Reported Dengue Cases in 2024
- 573,563
- Government Body
- ICMR
